================================================================================
CERVICAL AND THORACIC SPINE GUIDELINE - STATISTICAL ANALYSIS
================================================================================

**SOURCE DOCUMENT:** ACOEM Cervical and Thoracic Spine Disorders Guideline  
**EFFECTIVE DATE:** October 17, 2018  
**COPYRIGHT:** ©2020 Reed Group, Ltd. (ACOEM)  
**FULL TEXT AVAILABLE AT:** https://www.acoem.org/guidelines-resources/library/

**OFFICIAL MTUS ADOPTION:** California Code of Regulations, Title 8, Section 9792.20  
**MTUS REGULATIONS:** https://www.dir.ca.gov/dwc/MTUS/MTUS_Regulations.htm

================================================================================
STATISTICAL SUMMARY
================================================================================

**TOTAL RECOMMENDATIONS ANALYZED:** 162

**RECOMMENDATION BREAKDOWN:**

| Category | Count | Percentage |
|----------|-------|------------|
| Strongly Recommended | 13 | 8.0% |
| Recommended | 18 | 11.1% |
| Not Recommended | 7 | 4.3% |
| Insufficient Evidence | 124 | 76.5% |

**KEY FINDING:** 76.5% of all recommendations are "Insufficient Evidence"

================================================================================
FDA-APPROVED TREATMENTS DENIED
================================================================================

The following FDA-approved treatments receive "Insufficient Evidence" ratings:

**Medications:**
- Pregabalin (Lyrica) - FDA approved 2004
- Duloxetine (Cymbalta) - FDA approved 2004
- Milnacipran (Savella) - FDA approved 2009
- Various muscle relaxants

**Procedures:**
- Selective nerve root blocks
- Facet joint injections (certain types)
- Intradiscal electrothermal therapy (IDET)
- Percutaneous disc decompression

**Note:** Full indication details available in official ACOEM guideline at source URL above.

================================================================================
EVIDENCE QUALITY ANALYSIS
================================================================================

**ACOEM'S STATED METHODOLOGY:**
- Requires randomized controlled trials (RCTs) for "Strongly Recommended" status
- Excludes observational studies and real-world evidence
- Panel composition: See ACOEM official website for current members

**CRITICAL OBSERVATIONS:**
1. 76.5% "Insufficient Evidence" rate creates presumption of non-coverage
2. Evidence threshold appears higher than FDA approval standards
3. Cost considerations may influence recommendations (see ACOEM methodology)

================================================================================
CONSTITUTIONAL IMPLICATIONS
================================================================================

This guideline contributes to the systematic denial of FDA-approved treatments 
to California injured workers under the MTUS system.

**For full legal analysis, see:**
- MTUS_CONSTITUTIONAL_VIOLATION_MASTER_REPORT.txt
- MTUS_14TH_AMENDMENT_LEGAL_ARGUMENTS.txt

================================================================================
DISCLAIMER
================================================================================

This document contains statistical analysis and commentary only. All ACOEM 
guideline content remains copyright © Reed Group, Ltd. 

For the complete, official guideline text, visit:
https://www.acoem.org/guidelines-resources/library/

This analysis represents the author's independent research and opinions.

================================================================================
Document prepared: February 2026  
Classification: Research Analysis / Commentary  
================================================================================
